Clinical trials: Prostatic Disease
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC, Urogenital Neoplasms
- Trial name
- NCT05413850
- Testing
- Lutetium (177Lu) rhPSMA-10.1 Injection, 18F-rhPSMA-7.3 injection (in phase 1 only)
- Where
- 21 sites in United States, Belgium and 3 more
- Volunteers
- 82 people
- Sponsor
- Blue Earth Therapeutics Ltd
Breast Cancer, Lung Cancer
Blood Sample Collection to Evaluate Biomarkers in Subjects With Untreated Solid Tumors
The primary objective of this study is to obtain de-identified, clinically characterized, whole blood specimens to evaluate biomarkers associated with cancer for diagnostic assay development.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
- Trial name
- NCT03662204
- Testing
- Blood Sample Collection
- Where
- 119 sites in United States
- Volunteers
- 5,133 people
- Sponsor
- Exact Sciences Corporation
Benign Prostatic Hyperplasia
Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)
This study will evaluate the safety and effectiveness of different doses of OPK-88004 compared to placebo on serum PSA compared to placebo in men with benign prostatic hyperplasia (BPH).
- Trial name
- NCT03297398
- Testing
- Group-1 (15mg, OPK-88004), Group-2 (25 mg,OPK-88004)
- Where
- 15 sites in United States
- Volunteers
- 114 people
- Sponsor
- OPKO Health, Inc.
Prostate Cancer, Melanoma
Safety Study of MGA271 in Refractory Cancer
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.
- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT01391143
- Testing
- MGA271
- Where
- 12 sites in United States
- Volunteers
- 179 people
- Sponsor
- MacroGenics
Prostatic Neoplasms
A Study With BIBF 1120 in Patients With Hormone Refractory Prostate Cancer
The aim of this study was to evaluate the efficacy of two different doses of BIBF 1120 (250 mg twice daily versus 150 mg twice daily) in an exploratory manner.
- Trial name
- NCT02182063
- Testing
- BIBF 1120 low dose, BIBF 1120 high dose
- Volunteers
- 81 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant State
The purpose of the protocol is to describe treatment patterns among patients with prostate cancer prior to diagnosis of castration-resistant state.
- Trial name
- NCT01560858
- Where
- Spain
- Volunteers
- 407 people
- Sponsor
- Ipsen
Tumor
Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid Tumors
This is a study to assess the combination of PXD101 and 5-Fluorouracil (5-FU)in patients with advanced solid tumors. The primary goal of the study is to understand the safety, anti-tumor activity, and how the study drug behaves…
- Trial name
- NCT00413322
- Testing
- belinostat, 5-Fluorouracil (5-FU)
- Where
- 3 sites in United States
- Volunteers
- 35 people
- Sponsor
- Valerio Therapeutics
Prostate Cancer
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
ANDROMEDA is a first-in-human, Phase I/II, open-label, multicenter study of AZD9750 in participants with metastatic prostate cancer.
- Trial name
- ANDROMEDA (NCT07336446)
- Testing
- AZD9750, AZD5305
- Where
- 5 sites in United States, Australia and 2 more
- Volunteers
- 6 people
- Sponsor
- AstraZeneca
Prostatic Neoplasms
Phase II Trial of Monoclonal Antibody (J591) in Combination With Low-Dose Subcutaneous Interleukin-2
The monoclonal antibody J591 is being investigated as therapy for patients with prostate cancer, in combination with recombinant interleukin-2 (Proleukin, Aldesleukin).
- Trial name
- NCT00040586
- Testing
- Monoclonal Antibody J591, Recombinant Interleukin-2
- Where
- United States
- Sponsor
- BZL Biologics
Urinary Retention, Prostatic Hyperplasia
Clinical Trial in Males With BPH (Enlarged Prostate)
A study to determine the effect on prevention of Acute Urinary Retention (inability to urinate) in males with an enlarged prostate, also known as BPH. Free study-related medical care provided.
- Conditions
- Urinary Retention, Prostatic Hyperplasia, Benign Prostatic Hypertrophy
- Trial name
- NCT00029822
- Testing
- Alfuzosin (SL770499)
- Where
- 54 sites in United States, Australia and 15 more
- Volunteers
- 1,522 people
- Sponsor
- Sanofi
Prostatic Neoplasms, Neoplasm Metastasis
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
The purpose of this study is to learn whether adding abemaciclib to abiraterone plus prednisone prolongs the time before prostate cancer gets worse. Participation may last approximately 60 months.
- Conditions
- Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs
- Trial name
- CYCLONE 3 (NCT05288166)
- Testing
- Abemaciclib, Abiraterone, Prednisone or Prednisolone
- Where
- 266 sites in United States, Argentina and 22 more
- Volunteers
- 925 people
- Sponsor
- Eli Lilly and Company
Metastatic Prostate Cancer
Study of AZD0754 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate the safety, tolerability, and antitumour activity of AZD0754 CAR T-cell therapy in participants with metastatic prostate cancer.
- Trial name
- APOLLO (NCT06267729)
- Testing
- AZD0754, AZD2287
- Where
- 15 sites in United States, Australia and 1 more
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Prostatic Hyperplasia
MEN STUDY (ESTUDIO MEN) Quality of Life in Patients With BPH and Nocturia Before and After Tamsulosin Ocas® Treatment
This is an exploratory study, to evaluate the improvement in terms of quality of life that can be reached by a group of outpatients with BPH ( Benign Prostatic Hyperplasia ) and nocturia when they are under treatment with Secotex…
- Trial name
- NCT00885027
- Where
- 18 sites in Colombia
- Volunteers
- 1,342 people
- Sponsor
- Boehringer Ingelheim
Benign Prostatic Hyperplasia
GreenLight XPS Laser System Retrospective Chart Review
The purpose of this study is to gain information on the safety, efficacy, and quality of life in subjects who have had the GreenLight XPS procedure.
- Trial name
- NCT02139969
- Testing
- GreenLight XPS Laser System
- Where
- 6 sites in United States, Canada
- Volunteers
- 956 people
- Sponsor
- Boston Scientific Corporation
Prostate Cancer
Semi-automatic Download of Prostate Biopsy Cores While Keeping the Orientation, Unfolding and Unity of the Sample
Performance evaluation of a novel, semi-automated device and method for needle core biopsy download compared to standard methods in terms of: 1. Biopsy core length obtained (i.e. collecting all tissue fragments) 2.
- Trial name
- NCT01692405
- Testing
- NaviGo Bx™, biopsy sponge pad
- Where
- Israel
- Volunteers
- 436 people
- Sponsor
- UC Care, Ltd.
Prostate Cancer
Induction and Maintenance of Castration After Subcutaneous Injections of Triptorelin Pamoate in Patients With Prostate Cancer
Assess the efficacy and safety of Triptorelin pamoate 3M formulation (11.25mg) when administered by subcutaneous route.
- Trial name
- DKP 3M SC (NCT01715129)
- Testing
- Triptorelin Pamoate 11.25mg
- Where
- 12 sites in Bulgaria, France and 3 more
- Volunteers
- 126 people
- Sponsor
- Ipsen
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Saruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
The primary objective of this study is to measure efficacy of saruparib + physician's choice of ARPI compared with placebo + ARPI in men with metastatic hormone-sensitive prostate cancer (mHSPC) who have previously received…
- Trial name
- EvoPAR-PR05 (NCT07711002)
- Testing
- Saruparib, Enzalutamide, Darolutamide
- Where
- 210 sites in United States, Austria and 19 more
- Volunteers
- 1,330 people
- Sponsor
- AstraZeneca
Solid Tumors
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
The purpose of the Study is to select a dose and assess the safety and tolerability of INCB057643 as a monotherapy (Part 1 and Part 2) and in combination with standard-of-care (SOC) agents (Part 3 and Part 4) for subjects with…
- Trial name
- NCT02711137
- Testing
- INCB057643, Gemcitabine, Paclitaxel
- Where
- 18 sites in United States, Belgium and 1 more
- Volunteers
- 137 people
- Sponsor
- Incyte Corporation
Prostate Cancer
Investigating the Effects of Mikei® Red Reishi Essence EX on the Immune System of Prostate Cancer Patients and Patients With Non-cancerous Conditions of the Prostate
The primary objective of this study is to determine the effects of Mikei® Red Reishi Essence EX extract powder on the immune function of prostate cancer patients and patients with non-cancerous conditions of the prostate.
- Trial name
- NCT03589781
- Testing
- Mikei Red Reishi Essence EX
- Where
- United States
- Sponsor
- Nikkei (Canada) Marketing Limited
Prostatic Adenoma
Teverelix Evaluated in Advanced Prostate Cancer
The purpose of this study is to assess the safety and efficacy of teverelix TFA in the treatment of advanced prostate cancer
- Trial name
- TEACh (NCT04693507)
- Testing
- teverelix TFA 120 mg, teverelix TFA 180 mg
- Where
- 4 sites in Lithuania
- Volunteers
- 50 people
- Sponsor
- Antev Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.